Roche suffered a double blow on Friday as two clinical studies of drugs for breast cancer and Alzheimer's disease failed, sparking the biggest percentage fall in its stock in five years.
Double blow for Roche as breast cancer, Alzheimer's studies fail
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.